Ted Buchan & Co’s DexCom DXCM Stock Holding History

Ted Buchan & Co’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-3,439	Closed	-$477K	–	90
2024 Q1	$477K	Sell	3,439 -1,621	-32%	-$204K	0.29%	56
2023 Q4	$628K	Buy	5,060 +287	+6%	+$29.3K	0.46%	47
2023 Q3	$445K	Buy	4,773 +12	+0.3%	+$1.35K	0.36%	51
2023 Q2	$612K	Sell	4,761 -284	-6%	-$34.3K	0.47%	46
2023 Q1	$586K	Sell	5,045 -65	-1%	-$7.28K	0.49%	46
2022 Q4	$579K	Buy	+5,110	New	+$561K	0.54%	48

Other funds holding DXCM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Ted Buchan & Co's DXCM Position: Q2 2024 in Review

Ted Buchan & Co sold out of DexCom (DXCM) in Q2 2024, closing a stake of 3,439 shares — an estimated $477K sold.

Ted Buchan & Co first reported a position in DXCM in Q4 2022 and held it in 6 quarters. The position peaked at $628K in Q4 2023. 999 funds tracked by Wall St. Rank hold DXCM as of Q2 2024.

Ted Buchan & Co reported no remaining DexCom position as of Q2 2024 after selling out during the quarter.
Ted Buchan & Co sold 3,439 DexCom shares in Q2 2024, an estimated $477K.
Ted Buchan & Co first reported a position in DexCom in Q4 2022 and held it in 6 quarters.
Ted Buchan & Co's DexCom position peaked at $628K in Q4 2023.
999 funds tracked by Wall St. Rank held DexCom as of Q2 2024.

Based on Ted Buchan & Co's 13F filing for Q2 2024, filed 21 Aug 2024.